Resverlogix Reschedules Update Webcast and Conference Call
27 janv. 2021 17h36 HE
|
Resverlogix Corp
CALGARY, Alberta, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Company") (TSX:RVX) announces that it has postponed the webcast and conference call, previously...
Resverlogix Announces Update Webcast and Conference Call
18 janv. 2021 07h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today announced that on January 28th, 2021 at 10:00 am MT, it will be hosting a...
Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
12 janv. 2021 08h00 HE
|
Resverlogix Corp
CALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone and...
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
22 déc. 2020 17h17 HE
|
Resverlogix Corp
CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in...
Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
22 déc. 2020 07h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce recent published findings in the high-impact journal,...
Resverlogix Files Notice of Annual and Special Meeting of Shareholders
20 nov. 2020 18h28 HE
|
Resverlogix Corp
CALGARY, Alberta, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the filing on SEDAR (www.sedar.com) of the Notice of Meeting and...
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
12 nov. 2020 08h00 HE
|
Resverlogix Corp
Publication Explores the Beneficial Effects of Apabetalone on the Immune Cells of Diabetic Patients Event Reminder: Multiple Presentations on Apabetalone to be made during the American Heart...
Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
02 nov. 2020 07h30 HE
|
Resverlogix Corp
Significantly Strengthens Intellectual Property Portfolio and Apabetalone’s Commercial Runway Position Through 2040 BETonMACE Results Show Significant Improvement of Key Markers of Diabetes and Renal...
将Resverlogix临床候选药物apabetalone列为潜在新冠肺炎治疗方法（包括减少细胞因子风暴）的第二篇文章发表
26 oct. 2020 12h00 HE
|
Resverlogix Corp
阿尔伯塔省卡尔加里, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp.（以下称"Resverlogix"或“公司”）（TSX:RVX）今日宣布，同行评议期刊《Medicine in Drug Discovery》（新药发现医学）发表重点介绍该公司后期临床研究候选药物apabetalone的文章，题为“新冠肺炎导致多器官受损的蛋白驱动机理”。...
Resverlogix 臨床候選藥物 Apabetalone 因具有潛在治療新型冠狀病毒 COVID-19 功效，包括減少細胞因子風暴，而在第二份出版物入圍。
26 oct. 2020 12h00 HE
|
Resverlogix Corp
艾伯塔省卡爾加里, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp.（「Resverlogix」或「公司」）(TSX:RVX) 今天宣佈，其晚期臨床候選藥物 apabetalone 在同行評審期刊《Medicine in Drug Discovery》最近一篇標題為： 「Protein-driven mechanism of...